Veloxis logo

Veloxis

Europe, Hovedstaden, Denmark, Hørsholm

Description

Veloxis is a speciality pharmaceutical company focused on the development and commercialization of Envarsus.

Investor Profile

Veloxis has backed more than 1 startups, with 0 new investments in the last 12 months alone. The firm has led 1 rounds, about 100% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Convertible Note rounds (top funding stages).
  • Majority of deals are located in The Netherlands.
  • Strong thematic focus on Biotechnology, Life Science, Therapeutics.

Stage Focus

  • Convertible Note (100%)

Country Focus

  • The Netherlands (100%)

Industry Focus

  • Biotechnology
  • Life Science
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Veloxis frequently co-invest with?

OostNL
Europe, Gelderland, The Netherlands, Apeldoorn
Co-Investments: 1
Medicxi
Europe, England, United Kingdom, London
Co-Investments: 1
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 1
S
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 1

What are some of recent deals done by Veloxis?

Xenikos

Nijmegen, Gelderland, The Netherlands

Xenikos is developing a combination of two toxin-loaded anti-T-cell antibodies.

BiotechnologyLife ScienceTherapeutics
Convertible NoteSep 8, 2021
Amount Raised: $47,275,792